Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. - Wikidata - awgldk - TriplyDB

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.

http://www.wikidata.org/entity/Q35212113

about

Biomarker development in MET-targeted therapy The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Second-line systemic therapy for metastatic colorectal cancer.Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy Can we unlock the potential of IGF-1R inhibition in cancer therapy?Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3 The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study Incomplete target neutralization by the anti-cancer antibody rilotumumab.Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.Potential role of rilotumumab in the treatment of gastric cancer.Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.Promise and challenges on the horizon of MET-targeted cancer therapeutics Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Development of antibody-based c-Met inhibitors for targeted cancer therapy.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.

P2860

Q26751332-04A7E29D-E052-40F6-9253-2CF46840349A Q26777125-1E0FD500-B0A5-46FD-BFD8-53A9AB7F2EB3 Q26798408-CA0FB249-98CD-4332-8A53-5E86942D3570 Q28076490-26ABB71C-AB3E-41E6-9C3D-6341439F2797 Q30238760-03868AAE-C37F-4460-865E-F2BDAEFDCB9F Q30313824-F9370A65-BF11-4032-832B-8419F779DD8E Q30316105-9C9F8C0F-8A1A-4D21-A316-D09C5C04514D Q33618725-98C6EAFA-01F9-45DE-A0AB-CB316ADE9FEA Q33710179-D021639D-60C2-4377-AE92-191A4F973099 Q34336988-E74BF680-1F7F-4797-8313-90A695EDB2B1 Q34659512-39F3E702-4ACB-4464-8C64-173C569F45C2 Q35609517-E710F1EE-CC1B-4685-A197-53D1C3D115C8 Q35674206-E50FD45C-C8FF-4C33-BD3B-D526D9EF2028 Q36050773-17BB9B4A-4C6A-4093-BCD4-78087C472B62 Q37138513-8DB7509A-7A21-4A9B-9D1B-7B5F6E5B8CC1 Q37175089-12038ABC-3581-49BD-AEE6-D96C4E9BE534 Q38294088-3C80FA58-DC3F-4DFE-9537-DB38E646882E Q38442573-A5BF7410-F557-4464-9506-4E8153CD9CD8 Q38502350-A1716CC2-BC6C-45FE-AC96-A0D5A8E84810 Q38641329-1B12FF78-D7D8-4898-B40C-9006C8665E7C Q38648300-62CA0633-EFDF-42DA-A766-E28951BC29AE Q38771978-D12E464F-1F48-40D8-83DE-BD09E1FFA96D Q38794338-0A5416C3-8505-48CC-AC4B-AC08E8C381B4 Q38827897-66D373C8-8E34-4388-8FCE-7279F25B7289 Q38856729-A2591F78-E966-4ED9-97B0-A3F64522C2A8 Q38912279-FCB68443-4F5D-4D3F-972A-6EED0EA8A603 Q38941928-AFD0E6F8-EB43-451F-8295-EB443E976353 Q41511106-C639ABF9-689E-4D28-B00B-1494C8F14786 Q41825773-AD88ACF4-C75E-4E22-A31D-84142492F9CF Q41925374-76F1DB23-1DB0-47E7-A13E-3610A12FF2DF Q45305367-B4E595EC-8AC2-408C-8590-E1A9545F2064 Q47130146-E0757258-C717-42A4-9BC1-440DF4CEA25A Q47177133-7DD2BA61-20E1-4ADB-A3F2-E4DFC9CD6ABB Q47221234-70CD0A75-C5C8-42DB-A9B1-00CD12E73796 Q47897098-4B4F40B4-AF1A-4953-BA06-77A918E4E498 Q50985091-E753E166-E6F9-4875-9E18-FA02FB258D83

P2860

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.

http://www.wikidata.org/entity/Q35212113

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@ast

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@en

type

label

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@ast

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@en

prefLabel

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@ast

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@en

P1433

Q35212113-F42D4829-6B51-4114-AC58-743269F99C7C

P1476

Q35212113-18EF2189-E46E-4866-86AB-9ABF4C15899E

P2093

Q35212113-114A0AE8-D289-4401-A48C-7B05D2ECD0F6

Q35212113-124E7C2B-AF6E-479E-9355-7695ADB82AAC

Q35212113-16DD2254-1176-4DFC-916B-0DEC9637AC9B

Q35212113-33EACB65-727A-4162-8544-686EBA0EA781

Q35212113-5013C064-7591-44C0-982B-CAED4AE7A89A

Q35212113-7A4A11E5-036C-4D00-8C76-CAA55D7F7AB8

Q35212113-7FC35216-CF0C-4BAF-BBAB-B613359DF701

Q35212113-9715AC2A-A82B-43BC-9373-D79A8BE80755

Q35212113-AA839D7B-382C-4FAC-A4E7-46DA5C70FB9E

Q35212113-AD7A1492-F513-481A-A9C3-FD3DA1544648

P2860

Q35212113-019F2FC8-5C2C-4AF0-990B-4C424A217074

Q35212113-03F95732-8C55-47DF-A4A5-799A268B509E

Q35212113-05990470-D21F-430A-A40D-B902D88D1F5D

Q35212113-082AF627-542A-4299-A667-60159519D2D0

Q35212113-160EA972-0E15-450D-8265-9DEB7B9EE244

Q35212113-2297D5D0-6E7C-417D-AD48-74C56DB36A64

Q35212113-292189F6-039C-460B-979A-40CB484BE8BE

Q35212113-30F64BDE-E851-4C00-9D11-2852E05CBE74

Q35212113-3297128B-EAC6-46E9-A98D-E8DA452D31CB

Q35212113-54BCF38A-9C81-460B-A864-2CD72D2810E5

P304

Q35212113-C017DAFC-1BEF-4168-A1BD-5BBC95722F86

P31

Q35212113-7B95B9AD-5D47-4615-975B-F685962CC4E3

P356

Q35212113-A9E743DE-AFCA-4E79-8F7E-9A7E7FB25A0A

P407

Q35212113-A9699086-2738-444A-BF3D-FB9BAAEE40BD

P433

Q35212113-5A48B1F9-B0DB-4FBB-A860-7FE3481E7C48

P478

Q35212113-502FB146-7BBC-4696-B232-88A472D3EF64

P50

Q35212113-53497392-601A-4A39-AFC0-2D4383C7B34D

Q35212113-633224B2-B05E-4457-A9E8-5B16D1945EED

P577

Q35212113-03709CE8-7C83-4585-984A-5E94FBB0D356

P5875

Q35212113-38150333-F3FF-4C0D-8016-E5F680F1FA8D

P698

Q35212113-FD1ACC3C-124B-4420-8940-233127117298

P921

Q35212113-9894E40E-7875-4AC4-B359-BB891D047182

P932

Q35212113-E5598186-5FBC-4DE4-B59D-DC3D3487E1A0

P356

1078-0432.CCR-13-2752

P1433

Clinical Cancer Research

P1476

Randomized phase Ib/II trial o ...... metastatic colorectal cancer.

@en

P2093

Anna Swieboda-Sadlej

http://www.w3.org/2001/XMLSchema#string

Cathy Eng

http://www.w3.org/2001/XMLSchema#string

Dominic Smethurst

http://www.w3.org/2001/XMLSchema#string

Edith Mitchell

http://www.w3.org/2001/XMLSchema#string

Elena Elez

http://www.w3.org/2001/XMLSchema#string

Elwyn Loh

http://www.w3.org/2001/XMLSchema#string

Elzbieta Nowara

http://www.w3.org/2001/XMLSchema#string

Hans Prenen

http://www.w3.org/2001/XMLSchema#string

Hongjie Deng

http://www.w3.org/2001/XMLSchema#string

Ian McCaffery

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Met, metastasis, motility and more

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

ERBB receptors and cancer: the complexity of targeted inhibitors

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Gene expression profiles in normal and cancer cells

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

P304

4240-4250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-2752

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Eric Van Cutsem

Josep Tabernero

P577

2014-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263056703

http://www.w3.org/2001/XMLSchema#string

P698

24919569

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4371780

http://www.w3.org/2001/XMLSchema#string